Publication: Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the Implant
Authors
Gómez, J. ; Cánovas, E. ; Baños, V. ; Martínez, L. ; García-Vázquez, Elisa ; Hernández-Torres, A. ; Canteras, M. ; Ruiz, J. ; Medina, M. ; Martínez, P. ; Cánovas, A. ; Soriano, A. ; Clavel, M.
item.page.secondaryauthor
item.page.director
Publisher
American Society for Microbiology
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1128/aac.00352-11
item.page.type
info:eu-repo/semantics/article
Description
©2011, American Society for Microbiolog. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/. This document is the Published, version of a Published Work that appeared in final form in Antimicrobial Agents and Chemotherapy . To access the final edited and published work see https://doi.org/10.1128/aac.00352-11
Abstract
The aim of this study is to describe our experience with linezolid plus rifampin as a salvage therapy in
prosthetic joint infections (PJIs) when other antibiotic regimens failed or were not tolerated. A total of 161
patients with a documented prosthetic joint infection were diagnosed with a PJI and prospectively followed up
from January 2000 to April 2007. Clinical characteristics, inflammatory markers, microbiological and radio-
logical data, and antibiotic treatment were recorded. After a 2-year follow-up, patients were classified as cured
when the prosthesis was not removed, symptoms of infection disappeared, and inflammatory parameters were
within the normal range. Any other outcome was considered a failure. The mean age of the entire cohort (n
161) was 67 years. Ninety-five episodes were on a knee prosthesis (59%), and 66 were on a hip prosthesis (41%).
A total of 49 patients received linezolid plus rifampin: 45 due to failure of the previous antibiotic regimen and
4 due to an adverse event associated with the prior antibiotics. In no case was the implant removed. The mean
(standard deviation) duration of treatment was 80.2 (29.7) days. The success rate after 24 months of follow-up
was 69.4% (34/49 patients). Three patients developed thrombocytopenia and 3 developed anemia; however, it
was not necessary to stop linezolid. Linezolid plus rifampin is an alternative salvage therapy when the implant
is not removed.
publication.page.subject
Citation
Antimicrobial Agents and Chemotherapy. 2011, 55(9):4308–4310
item.page.embargo
Collections
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/